We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · December 08, 2021

Poziotinib in Previously Treated NSCLC Harboring HER2 Exon 20 Insertion Mutations

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
J. Clin. Oncol 2021 Nov 29;[EPub Ahead of Print], X Le, R Cornelissen, M Garassino, JM Clarke, N Tchekmedyian, JW Goldman, SY Leu, G Bhat, F Lebel, JV Heymach, MA Socinski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading